Quarterly ResultAug 5, 2026, 04:23 PM
Vaxcyte Q2 Net Loss Widens to $284.3M; R&D Expenses Up 38.9%
AI Summary
Vaxcyte reported a net loss of $284.3 million for Q2 2026, widening from $166.6 million in Q2 2025, primarily due to a 38.9% increase in research and development expenses to $267.9 million. For the six months ended June 30, 2026, the net loss reached $604.9 million. The company also noted the August 1, 2026, handover of its dedicated manufacturing suite to Lonza and its 15-year manufacturing agreement with Thermo Fisher Scientific.
Key Highlights
- Q2 2026 net loss was $284.3 million, compared to $166.6 million in Q2 2025.
- Q2 2026 R&D expenses increased 38.9% to $267.9 million from $194.2 million in Q2 2025.
- Net loss for the six months ended June 30, 2026, was $604.9 million.
- Total assets increased to $3.14 billion as of June 30, 2026, from $3.00 billion at year-end 2025.
- Cash and cash equivalents were $183.2 million as of June 30, 2026.
- Lonza manufacturing suite handed over on August 1, 2026, for PCV candidate production.
- Entered 15-year manufacturing agreement with Thermo Fisher Scientific in September 2025.
- Net cash provided by financing activities was $607.3 million for the six months.
Price Impact
More from PCVX